Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01776554 · ClinicalTrials.gov registry record · Phase 2

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children

A Phase 2 study of Pandemic H5N1 Influenza, sponsored by Novartis Vaccines.

Completed
Registry status
Phase 2
Development phase
662
Enrollment target
12
Study locations

NCT01776554: Completed Phase 2 study of Pandemic H5N1 Influenza, sponsored by Novartis Vaccines.

NCT01776554 is a Phase 2 study of Pandemic H5N1 Influenza that has completed, run by Novartis Vaccines. The registered enrollment target is 662 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (398% higher). The trial reports 12 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01776554, a Phase 2 study of Pandemic H5N1 Influenza, has completed, sponsored by Novartis Vaccines.

COMPLETED
Registry status
Phase 2
Development phase
662 participants
Enrollment target
12
Study locations

Study Summary

Evaluate Safety, Tolerability and Immune response of adjuvanted H5N1 cell culture derived influenza vaccine in children.

Primary Outcome

The optimal aH5N1c vaccine formulation was evaluated in terms of percentages of subjects aged 6 to \<36 months, achieving HI titers ≥40 against homologous A/H5N1 strain, three weeks after second vaccination with either low dose or high dose of aH5N1c vaccine, according to the Center for Biologics Evaluation and Research (CBER) criterion. As there is no CBER criteria defined for children, immunogenicity was evaluated using CBER criterion applicable for adults (18-64 years). CBER criterion is me

Conditions Studied

Interventions

  • BIOLOGICAL Adjuvanted H5N1 pandemic influenza vaccine

Study Locations (12)

Kansas

  • 7 Heartland Research Associates - Newton
  • 5 Heartland Research Associates - Wichita
  • 9 Heartland Research Associates - Wichita

Utah

  • 8 Foothill Family Clinic - Salt Lake City
  • 4 Foothill Family Clinic - South Cottonwood Heights

Other

  • 75 Phramongkutklao Hospital - Bangkok
  • 76 Faculty of Tropical Medicine Mahidol University - Bangkok

Florida

  • 3 Meridian Clinical Research - Miami

Missouri

  • 1 Saint Louis University - St Louis

Nebraska

  • 6 Meridian Clinical Research - Omaha

Texas

  • 10 Tekton Research - Georgetown

Washington

  • 2 Rockwood Clinic P S - Spokane

Trial Details

FieldValue
Enrollment Target 662 participants
Start Date 2013-01
Est. Completion 2014-06
Phase Phase 2
Novartis Vaccines

32 total trials

What the finished NCT01776554 record still lists

NCT01776554 is an interventional study that assigns participants to a tested intervention. The registered 662 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (398% higher).

The record links to 1 condition, with Pandemic H5N1 Influenza appearing as the primary indexed condition, and to 1 intervention - of which Adjuvanted H5N1 pandemic influenza vaccine is the first listed.

NCT01776554 lists 12 locations in 8 states (Kansas, Utah, Other).

Frequently Asked Questions

What is clinical trial NCT01776554 about?

NCT01776554 is a clinical study titled "Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children". Evaluate Safety, Tolerability and Immune response of adjuvanted H5N1 cell culture derived influenza vaccine in children.

What is the current status of trial NCT01776554?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 662 participants. The study started on 2013-01. Estimated completion is 2014-06.

What conditions does trial NCT01776554 study?

This clinical trial studies the following conditions: Pandemic H5N1 Influenza.

What interventions are being tested in trial NCT01776554?

The interventions under investigation include: Adjuvanted H5N1 pandemic influenza vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT01776554?

This trial is sponsored by Novartis Vaccines, which has 32 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01776554 being conducted?

This trial has 12 study locations across Florida, Kansas, Missouri, Nebraska, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT01776554's enrollment target sits among peer trials

662 49th of 2000 higher than 1,952 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05254743 · 662 participants · Phase 3

    A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  • NCT07164443 · 663 participants · Phase 3

    A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  • NCT06607341 · 664 participants · NA

    Community Engagement Alliance Against Disparities

  • NCT01185132 · 660 participants · Phase 3

    Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01776554, the US trial registry maintained by the National Library of Medicine. NCT01776554 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.